{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:18:57Z","timestamp":1792592337583,"version":"4.5.0"},"reference-count":309,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"crossref","award":["310334\/2019-5"],"award-info":[{"award-number":["310334\/2019-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-021-08918-6","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T06:02:48Z","timestamp":1646373768000},"page":"251-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Role of Autoantibody Testing in Modern Personalized Medicine"],"prefix":"10.1007","volume":"63","author":[{"given":"Cristiane","family":"Kayser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edvia Almeida","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgard Torres","family":"dos Reis-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlles Heldan de Moura","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin J.","family":"Fritzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8742-9931","authenticated-orcid":false,"given":"Luis Eduardo C.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"8918_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/gm178","volume":"2","author":"C Auffray","year":"2010","unstructured":"Auffray C, Charron D, Hood L (2010) Predictive, preventive, personalized and participatory medicine: Back to the future. Genome Med 2:57","journal-title":"Genome Med"},{"key":"8918_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.autrev.2014.10.003","volume":"14","author":"G Yaniv","year":"2015","unstructured":"Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O et al (2015) A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev 14:75\u201379","journal-title":"Autoimmun Rev"},{"key":"8918_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","volume":"96","author":"A Fava","year":"2019","unstructured":"Fava A, Petri M (2019) Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun 96:1\u201313","journal-title":"J Autoimmun"},{"key":"8918_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","volume":"39","author":"GJ Pons-Estel","year":"2010","unstructured":"Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39:257\u2013268","journal-title":"Semin Arthritis Rheum"},{"key":"8918_CR5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1191\/0961203302lu244xx","volume":"11","author":"MJ Vilar","year":"2002","unstructured":"Vilar MJ, Sato EI (2002) Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). Lupus 11:528\u2013532","journal-title":"Lupus"},{"key":"8918_CR6","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78:1151\u20131159","journal-title":"Ann Rheum Dis"},{"key":"8918_CR7","doi-asserted-by":"crossref","unstructured":"Fernandez SA, Lobo AZ, Oliveira ZN, Fukumori LM, P\u00e9rigo AM, Rivitti EA (2003) Prevalence of antinuclear autoantibodies in the serum of normal blood donors. Rev Hosp Clin Fac Med Sao Paulo. 58:315\u2013319","DOI":"10.1590\/S0041-87812003000600005"},{"key":"8918_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/art.30084","volume":"63","author":"HA Mariz","year":"2011","unstructured":"Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE (2011) Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63:191\u2013200","journal-title":"Arthritis Rheum"},{"key":"8918_CR9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/art.41214","volume":"72","author":"GE Dinse","year":"2020","unstructured":"Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC et al (2020) Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol 72:1026\u20131035","journal-title":"Arthritis Rheumatol"},{"key":"8918_CR10","doi-asserted-by":"crossref","unstructured":"Dellavance A, Gabriel AJ, Nuccitelli B, Taliberti T, von M\u00fchlen C, Bichara CDA et al (2009) Third Brazilian consensus for autoantibody research in HEp-2 cells (FAN). Recommendations for standardization of the autoantibody screening assay in HEp-2 cells, quality control and clinical associations. Rev Bras Rheumatol 49:89\u2013109","DOI":"10.1590\/S0482-50042009000200002"},{"key":"8918_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","volume":"78","author":"J Damoiseaux","year":"2019","unstructured":"Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ et al (2019) Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 78:879\u2013889","journal-title":"Ann Rheum Dis"},{"key":"8918_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fimmu.2015.00412","volume":"6","author":"EKL Chan","year":"2015","unstructured":"Chan EKL, Damoiseaux J, Carballo OG, Conrad K, Cruvinel WM, Francescantonio PLC et al (2015) Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014\u20132015. Front Immunol 6:412","journal-title":"Front Immunol"},{"key":"8918_CR13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/art.24699","volume":"61","author":"DJ Wallace","year":"2009","unstructured":"Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT et al (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61:1168\u20131178","journal-title":"Arthritis Rheum"},{"key":"8918_CR14","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov\u00e1 D et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918\u20133930","journal-title":"Arthritis Rheum"},{"key":"8918_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1515\/cclm-2019-0638","volume":"58","author":"MS Prado","year":"2020","unstructured":"Prado MS, Dellavance A, Rodrigues SH, Marvulle V, Andrade LEC (2020) Changes in the result of antinuclear antibody immunofluorescence assay on HEp-2 cells reflect disease activity status in systemic lupus erythematosus. Clin Chem Lab Med 58:1271\u20131281","journal-title":"Clin Chem Lab Med"},{"key":"8918_CR16","doi-asserted-by":"crossref","unstructured":"Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J et al (2018) Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort. Arthritis Care Res (Hoboken) 71:893\u2013902","DOI":"10.1002\/acr.23712"},{"key":"8918_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/B978-1-4377-1893-5.00043-1","volume-title":"Dubois' lupus erythematosus and related syndromes","author":"F Quismorio","year":"2013","unstructured":"Quismorio F, Torralba K (2013) Clinical application of serologic tests, serum protein abnormalities, and other clinical laboratory test in SLE. In: Wallace D, Hahn B (eds) Dubois\u2019 lupus erythematosus and related syndromes, 8th edn. Elsevier Saunders, Philadelphia, PA, pp 526\u2013540","edition":"8"},{"key":"8918_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrrheum.2015.29","volume":"11","author":"P Brito-Zer\u00f3n","year":"2015","unstructured":"Brito-Zer\u00f3n P, Izmirly P, Ramos-Casals M, Buyon J, Khamashta M (2015) The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 11:301\u2013312","journal-title":"Nat Rev Rheumatol"},{"key":"8918_CR19","first-page":"464","volume-title":"Dubois\u2019 lupus erythematosus and related syndromes","author":"M Wahren-Herlenius","year":"2012","unstructured":"Wahren-Herlenius M, Sonesson SE, Clowse ME (2012) Neonatal lupus erythematosus. In: Wallace D, Hahn B (eds) Dubois\u2019 lupus erythematosus and related syndromes, 8th edn. Saunders, Philadelphia, pp 464\u2013472","edition":"8"},{"key":"8918_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/art.41191","volume":"72","author":"L Sammaritano","year":"2020","unstructured":"Sammaritano L, Bermas B, Chakravarty E, Chambers C, Clowse M, Lockshin M et al (2020) 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 72:529\u2013556","journal-title":"Arthritis Rheumatol"},{"key":"8918_CR21","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/art.20130","volume":"50","author":"PE Lazzerini","year":"2004","unstructured":"Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G et al (2004) Prolongation of the corrected QT interval in adult patients with anti-Ro\/SSA-positive connective tissue diseases. Arthritis Rheum 50:1248\u20131252","journal-title":"Arthritis Rheum"},{"key":"8918_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.amjcard.2007.04.048","volume":"100","author":"PE Lazzerini","year":"2007","unstructured":"Lazzerini PE, Capecchi PL, Guideri F, Bellisai F, Selvi E, Acampa M et al (2007) Comparison of frequency of complex ventricular arrhythmias in patients with positive versus negative anti-Ro\/SSA and connective tissue disease. Am J Cardiol 100:1029\u20131034","journal-title":"Am J Cardiol"},{"key":"8918_CR23","first-page":"237","volume-title":"Lupus erythematosus: basic, applied and clinical aspects","author":"M Satoh","year":"2020","unstructured":"Satoh M, Fritzler MF, Chan EKL (2020) Antihistone and antispliceosome antibodies. In: Tsokos GC (ed) Lupus erythematosus: basic, applied and clinical aspects, 1st edn. Academic Press, New York, pp 237\u2013247","edition":"1"},{"key":"8918_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1191\/0961203302lu144oa","volume":"11","author":"R Furtado","year":"2002","unstructured":"Furtado R, Pucinelli M, Cristo V, Andrade L, Sato E (2002) Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud\u2019s phenomenon in SLE patients. Lupus 11:35\u201341","journal-title":"Lupus"},{"key":"8918_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/08916930400022715","volume":"38","author":"P Migliorini","year":"2005","unstructured":"Migliorini P, Baldini C, Rocchi V, Bombardieri S (2005) Anti-Sm and anti-RNP antibodies. Autoimmunity 38:47\u201354","journal-title":"Autoimmunity"},{"key":"8918_CR26","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/ard.62.6.556","volume":"62","author":"P Alba","year":"2003","unstructured":"Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I et al (2003) Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: Significant factors associated with lupus nephritis. Ann Rheum Dis 62:556\u2013560","journal-title":"Ann Rheum Dis"},{"key":"8918_CR27","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF van Vollenhoven","year":"2014","unstructured":"van Vollenhoven RF, Fly M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:958\u2013967","journal-title":"Ann Rheum Dis"},{"key":"8918_CR28","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1002\/art.22198","volume":"54","author":"C Tseng","year":"2006","unstructured":"Tseng C, Buyon J, Kim M, Belmont H, Mackay M, Diamond B et al (2006) The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:3623\u20133632","journal-title":"Arthritis Rheum"},{"key":"8918_CR29","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1177\/0961203311417033","volume":"20","author":"W Hung","year":"2011","unstructured":"Hung W, Chen Y, Lan J, Chen H, Chen Y, Chen D et al (2011) Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis. Lupus 20:1404\u20131410","journal-title":"Lupus"},{"key":"8918_CR30","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/art.22356","volume":"55","author":"K Ng","year":"2006","unstructured":"Ng K, Manson J, Rahman A, Isenberg D (2006) Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 55:900\u2013904","journal-title":"Arthritis Rheum"},{"key":"8918_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s10875-012-9825-6","volume":"33","author":"M Sui","year":"2013","unstructured":"Sui M, Sui M, Lin Q, Xu Z, Han X, Xie R et al (2013) Simultaneous positivity for anti-DNA, anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis. J Clin Immunol 33:378\u2013387","journal-title":"J Clin Immunol"},{"key":"8918_CR32","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/0961203307078391","volume":"16","author":"LM Stinton","year":"2007","unstructured":"Stinton LM, Barr SG, Tibbles LA, Yilmaz S, Sar A, Benedikttson H et al (2007) Autoantibodies in lupus nephritis patients requiring renal transplantation. Lupus 16:394\u2013400","journal-title":"Lupus"},{"key":"8918_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1196\/annals.1313.020","volume":"1050","author":"R Sinico","year":"2005","unstructured":"Sinico R, Radice A, Ikehata M, Giammarresi G, Corace C, Arrigo G et al (2005) Anti-C1q autoantibodies in lupus nephritis: Prevalence and clinical significance. Ann New York Acad of Sci 1050:193\u2013200","journal-title":"Ann New York Acad of Sci"},{"key":"8918_CR34","first-page":"230","volume":"18","author":"C Siegert","year":"1991","unstructured":"Siegert C, Daha M, Westedt ML, van der Voort E, Breedveld F (1991) IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol 18:230\u2013234","journal-title":"J Rheumatol"},{"key":"8918_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0961203314547791","volume":"24","author":"A-M Orbai","year":"2015","unstructured":"Orbai A-M, Truedsson L, Sturfelt G, Nived O, Fang H, Alarc\u00f3n GS et al (2015) Anti- C1q antibodies in systemic lupus erythematosus. Lupus 24:42\u201349","journal-title":"Lupus"},{"key":"8918_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0961203310379871","volume":"20","author":"A Matrat","year":"2011","unstructured":"Matrat A, Veysseyre-Balter C, Trolliet P, Villar E, Dijoud F, Bienvenu J et al (2011) Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: Predictive value for renal flares. Lupus 20:28\u201334","journal-title":"Lupus"},{"key":"8918_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/ard.2008.094508","volume":"68","author":"G Moroni","year":"2009","unstructured":"Moroni G, Radice A, Giammarresi G, Quaglini S, Gallelli B, Leoni A et al (2009) Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 68:234\u2013237","journal-title":"Ann Rheum Dis"},{"key":"8918_CR38","doi-asserted-by":"crossref","unstructured":"Choi M, FitzPatrick R, Buhler K, Mahler M, Fritzler M (2020) A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun Rev 19:102463","DOI":"10.1016\/j.autrev.2020.102463"},{"key":"8918_CR39","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/kep142","volume":"48","author":"S Haddouk","year":"2009","unstructured":"Haddouk S, Marzouk S, Jallouli M, Fourati H, Frigui M, Hmida Y et al (2009) Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 48:953\u2013957","journal-title":"Rheumatology (Oxford)"},{"key":"8918_CR40","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1056\/NEJM198707303170503","volume":"317","author":"E Bonfa","year":"1987","unstructured":"Bonfa E, Golombek S, Kaufman L, Skelly S, Weissbach H, Brot N et al (1987) Association between lupus psychosis and anti-ribosomal P protein antibodies. New Eng J Med 317:265\u2013271","journal-title":"New Eng J Med"},{"key":"8918_CR41","doi-asserted-by":"crossref","unstructured":"do Nascimento A, Viana VDS, Testagossa LDA, Leon E, Borba E, Barros R et al (2006) Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. Arthritis Rheum 54:1568\u20131572","DOI":"10.1002\/art.21875"},{"key":"8918_CR42","doi-asserted-by":"crossref","unstructured":"Macedo P, Borba E, Viana VDS, Leon E, Testagossa L, Barros R et al (2011) Antibodies to ribosomal P proteins in lupus nephritis: is a surrogate marker for a better renal survival? Autoimmun Rev 10:126\u2013130","DOI":"10.1016\/j.autrev.2010.09.002"},{"key":"8918_CR43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/liv.12155","volume":"336","author":"A Calich","year":"2013","unstructured":"Calich A, Viana V, Cancado E, Tustumi F, Terrabuio D, Leon E et al (2013) Anti-ribosomal P protein: a novel antibody in autoimmune hepatitis. Liver Int 336:909\u2013913","journal-title":"Liver Int"},{"key":"8918_CR44","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.20433","volume":"50","author":"M Tektonidou","year":"2004","unstructured":"Tektonidou M, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos P, Moutsopoulos H (2004) Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies:Pprevalence, clinical associations, and long-term outcome. Arthritis Rheum 50:2569\u20132579","journal-title":"Arthritis Rheum"},{"key":"8918_CR45","doi-asserted-by":"crossref","unstructured":"Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA et al (2015) Haematological manifestations of lupus. Lupus Sci Med 2:e000078","DOI":"10.1136\/lupus-2014-000078"},{"key":"8918_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molimm.2015.03.007","volume":"67","author":"M Stegert","year":"2015","unstructured":"Stegert M, Bock M, Trendelenburg M (2015) Clinical presentation of human C1q deficiency: How much of a lupus? Mol Immunol 67:3\u201311","journal-title":"Mol Immunol"},{"key":"8918_CR47","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1177\/096120339700600509","volume":"6","author":"MNT Araujo","year":"1997","unstructured":"Araujo MNT, Silva NP, Andrade LEC, Sato EI, Gerbase-DeLima M, Leser PG (1997) C2 deficiency in blood donors and lupus patients: prevalence, clinical characteristics and HLA-associations in the Brazilian population. Lupus 6:462\u2013466","journal-title":"Lupus"},{"key":"8918_CR48","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1086\/518257","volume":"80","author":"Y Yang","year":"2007","unstructured":"Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B et al (2007) Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): Low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 80:1037\u20131054","journal-title":"Am J Hum Genet"},{"key":"8918_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s42358-019-0076-6","volume":"59","author":"KMC Pereira","year":"2019","unstructured":"Pereira KMC, Perazzio S, Faria AGA, Moreira ES, Santos VC, Grecco M et al (2019) Impact of C4, C4A and C4B gene copy number variation in the susceptibility, phenotype and progression of systemic lupus erythematosus. Adv Rheumatol 59:36\u201342","journal-title":"Adv Rheumatol"},{"key":"8918_CR50","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/bmj.287.6399.1088","volume":"287","author":"G Hughes","year":"1983","unstructured":"Hughes G (1983) Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 287:1088\u20131089","journal-title":"Br Med J (Clin Res Ed)"},{"key":"8918_CR51","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1073\/pnas.87.11.4120","volume":"87","author":"H McNeil","year":"1990","unstructured":"McNeil H, Simpson R, Chesterman C, Krilis S (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein I (apolipoprotein H). Proc Nati Acad Sci U S A 87:4120\u20134124","journal-title":"Proc Nati Acad Sci U S A"},{"key":"8918_CR52","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1182\/blood-2012-03-378646","volume":"120","author":"P Groot","year":"2012","unstructured":"Groot P, Urbanus R (2012) The significance of autoantibodies against \u03b22-glycoprotein I. Blood 120:266\u2013274","journal-title":"Blood"},{"key":"8918_CR53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R et al (2006) International consensus statement on an update of the classification criteria for a definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295\u2013306","journal-title":"J Thromb Haemost"},{"key":"8918_CR54","doi-asserted-by":"publisher","unstructured":"Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo MC, Avcin T, Bertolaccini ML et al (2020) Development of new international antiphospholipid syndrome classification criteria phase I\/II Report: Generation and reduction of candidate criteria. Arthritis Care Res (Hoboken). Online ahead of print: https:\/\/doi.org\/10.1002\/acr.24520","DOI":"10.1002\/acr.24520"},{"key":"8918_CR55","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","volume":"8","author":"R Urbanus","year":"2009","unstructured":"Urbanus R, Siegerink B, Roest M, Rosendaal F, de Groot P, Algra A (2009) Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 8:998\u20131005","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"8918_CR56","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/ijlh.13195","volume":"42","author":"KMJ Devreese","year":"2020","unstructured":"Devreese KMJ (2020) Testing for antiphospholipid antibodies: advances and best practices. Int J Lab Hematol 42(Suppl 1):49\u201358","journal-title":"Int J Lab Hematol"},{"key":"8918_CR57","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjh.12848","volume":"165","author":"D Jayakody Arachchillage","year":"2014","unstructured":"Jayakody Arachchillage D, Greaves M (2014) The checked history of the antiphospholipid syndrome. British J Haematol 165:609\u2013617","journal-title":"British J Haematol"},{"key":"8918_CR58","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.autrev.2013.11.004","volume":"13","author":"Q Reynaud","year":"2014","unstructured":"Reynaud Q, Lega J, Mismetti P, Chapelle C, Wahl D, Cath\u00e9bras P et al (2014) Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 13:595\u2013608","journal-title":"Autoimmun Rev"},{"key":"8918_CR59","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.thromres.2009.09.001","volume":"125","author":"SM Schouwers","year":"2010","unstructured":"Schouwers SM, Delanghe JR, Devreese KM (2010) Lupus anticoagulant (LAC) testing in patients with inflammatory status: Does C-reactive protein interfere with LAC test results? Thromb Res 125:102\u2013104","journal-title":"Thromb Res"},{"key":"8918_CR60","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/rheumatology\/ket126","volume":"52","author":"R Nayfe","year":"2013","unstructured":"Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta M (2013) Seronegative antiphospholipid syndrome. Rheumatology (Oxford) 52:1358\u20131367","journal-title":"Rheumatology (Oxford)"},{"key":"8918_CR61","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/art.38131","volume":"65","author":"V Murthy","year":"2013","unstructured":"Murthy V, Willis R, Romay-Penabad Z, Ruiz-Lim\u00f3n P, Mart\u00ednez-Mart\u00ednez L, Jatwani S et al (2013) Value of isolated IgA anti-\u03b22 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 65:3186\u20133193","journal-title":"Arthritis Rheum"},{"key":"8918_CR62","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1681\/ASN.2014030228","volume":"26","author":"J Morales","year":"2015","unstructured":"Morales J, Martinez-Flores J, Serrano M, Castro M, Alfaro F, Garc\u00eda F et al (2015) Association of early kidney allograft failure with preformed IgA antibodies to \u03b22-glycoprotein I. J Am Soc Nephrol (JASN) 26:735\u2013745","journal-title":"J Am Soc Nephrol (JASN)"},{"key":"8918_CR63","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1160\/TH13-06-0509","volume":"111","author":"S Sciascia","year":"2014","unstructured":"Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta M, Bertolaccini M (2014) Anti-prothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 111:354\u2013364","journal-title":"Thromb Haemost"},{"key":"8918_CR64","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.3389\/fimmu.2018.02971","volume":"9","author":"E Litvinova","year":"2018","unstructured":"Litvinova E, Darnige L, Kirilovsky A, Burnel Y, Luna G, Dragon-Durey M (2018) Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol 9:2971","journal-title":"Front Immunol"},{"key":"8918_CR65","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/art.33340","volume":"64","author":"K Otomo","year":"2012","unstructured":"Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K et al (2012) Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64:504\u2013512","journal-title":"Arthritis Rheum"},{"key":"8918_CR66","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","volume":"52","author":"S Sciascia","year":"2013","unstructured":"Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta M, Bertolaccini M (2013) GAPSS: The global anti-phospholipid syndrome score. Rheumatology (Oxford) 52:1397\u20131403","journal-title":"Rheumatology (Oxford)"},{"key":"8918_CR67","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1055\/s-0037-1603936","volume":"44","author":"M Radin","year":"2018","unstructured":"Radin M, Cecchi I, Roccatello D, Meroni P, Sciascia S (2018) Prevalence and thrombotic risk assessment of anti-\u03b22 Glycoprotein I domain I antibodies: a systematic review. Semin Thromb Hemost 44:466\u2013474","journal-title":"Semin Thromb Hemost"},{"key":"8918_CR68","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/jth.12865","volume":"13","author":"V Pengo","year":"2015","unstructured":"Pengo V, Ruffatti A, Tonello M, Cuffaro S, Banzato A, Bison E et al (2015) Antiphospholipid syndrome: Antibodies to Domain 1 of \u03b22-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 13:782\u2013787","journal-title":"J Thromb Haemost"},{"key":"8918_CR69","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/acr.23310","volume":"70","author":"H Nakamura","year":"2018","unstructured":"Nakamura H, Oku K, Amengual O, Ohmura K, Fujieda Y, Kato M et al (2018) First-line, non-criterial antiphospholipid antibody testing for the diagnosis of antiphospholipid syndrome in clinical practice: The combination of anti-\u03b2 2-glycoprotein I domain I and anti-phosphatidylserine\/prothrombin complex antibodies tests. Arthritis Care Res (Hoboken) 70:627\u2013634","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8918_CR70","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1160\/TH04-12-0839","volume":"93","author":"V Pengo","year":"2005","unstructured":"Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Ninety F, Iliceto S (2005) Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 93:1147\u20131152","journal-title":"Thromb Haemost"},{"key":"8918_CR71","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/acr.20098","volume":"62","author":"A Ruffatti","year":"2010","unstructured":"Ruffatti A, Calligaro A, Hoxha A, Trevisanuto D, Ruffatti A, Gervasi M et al (2010) Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 62:302\u2013307","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8918_CR72","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","volume":"49","author":"M Radin","year":"2019","unstructured":"Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou M, Ugarte A et al (2019) The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Semin Arthritis Rheum 49:464\u2013468","journal-title":"Semin Arthritis Rheum"},{"key":"8918_CR73","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.reuma.2012.09.001","volume":"9","author":"R Burgos-Vargas","year":"2013","unstructured":"Burgos-Vargas R, Catoggio LJ, Galarza-Maldonado C, Ostojich K, Cardiel MH (2013) Current therapies in rheumatoid arthritis: a Latin American perspective. Reumatol Clin 9:106\u2013112","journal-title":"Reumatol Clin"},{"key":"8918_CR74","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS et al (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001","journal-title":"Nat Rev Dis Primers"},{"key":"8918_CR75","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/BOR.0000000000000708","volume":"32","author":"HK Greenblatt","year":"2020","unstructured":"Greenblatt HK, Kim HA, Bettner LF, Deane KD (2020) Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. Curr Opin Rheumatol 32:289\u2013296","journal-title":"Curr Opin Rheumatol"},{"key":"8918_CR76","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699","journal-title":"Ann Rheum Dis"},{"key":"8918_CR77","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/ijms22020686","volume":"22","author":"CY Wu","year":"2021","unstructured":"Wu CY, Yang HY, Luo SF, Lai JH (2021) From rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis. Int J Mol Sci 22:686","journal-title":"Int J Mol Sci"},{"key":"8918_CR78","doi-asserted-by":"crossref","unstructured":"Aletaha D (2020) Precision medicine and management of rheumatoid arthritis. J Autoimmun 110:102405","DOI":"10.1016\/j.jaut.2020.102405"},{"key":"8918_CR79","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/1744666X.2020.1771183","volume":"16","author":"JR Tarn","year":"2020","unstructured":"Tarn JR, Lendrem DW, Isaacs JD (2020) In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis. Expert Rev Clin Immunol 16:621\u2013630","journal-title":"Expert Rev Clin Immunol"},{"key":"8918_CR80","doi-asserted-by":"publisher","unstructured":"Bettner LF, Peterson RA, Bergstedt DT, Kelmenson LB, Demoruelle MK, Mikuls TR et al (2021) Combinations of anticyclic citrullinated protein antibody, rheumatoid factor, and serum calprotectin positivity are associated with the diagnosis of rheumatoid arthritis within 3 years. ACR Open Rheumatol 20. https:\/\/doi.org\/10.1002\/acr2.11309","DOI":"10.1002\/acr2.11309"},{"key":"8918_CR81","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/art.41417","volume":"73","author":"KD Deane","year":"2021","unstructured":"Deane KD, Holers VM (2021) Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift. Arthritis Rheumatol 73:181\u2013193","journal-title":"Arthritis Rheumatol"},{"key":"8918_CR82","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/0002-9343(83)90471-0","volume":"75","author":"AT Masi","year":"1983","unstructured":"Masi AT (1983) Articular patterns in the early course of rheumatoid arthritis. Am J Med 75:16\u201326","journal-title":"Am J Med"},{"key":"8918_CR83","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature01661","volume":"423","author":"GS Firestein","year":"2003","unstructured":"Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356\u2013361","journal-title":"Nature"},{"key":"8918_CR84","doi-asserted-by":"crossref","unstructured":"Trouw LA, Huizinga TW, Toes RE (2013) Autoimmunity in rheumatoid arthritis: Different antigens\u2014common principles. Ann Rheum Dis 72(Suppl 2):ii132\u2013ii136","DOI":"10.1136\/annrheumdis-2012-202349"},{"key":"8918_CR85","doi-asserted-by":"crossref","unstructured":"Carubbi F, Alunno A, Gerli R, Giacomelli R (2019) Post-translational modifications of proteins: Novel insights in the autoimmune response in rheumatoid arthritis. Cells 8(7):657","DOI":"10.3390\/cells8070657"},{"key":"8918_CR86","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaut.2017.06.004","volume":"84","author":"C Gr\u00f6nwall","year":"2017","unstructured":"Gr\u00f6nwall C, Amara K, Hardt U, Krishnamurthy A, Steen J, Engstrom M et al (2017) Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesis. J Autoimmun 84:29\u201345","journal-title":"J Autoimmun"},{"key":"8918_CR87","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/annrheumdis-2014-206785","volume":"75","author":"M Juarez","year":"2016","unstructured":"Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I et al (2016) Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis 75:1099\u20131107","journal-title":"Ann Rheum Dis"},{"key":"8918_CR88","doi-asserted-by":"publisher","first-page":"17372","DOI":"10.1073\/pnas.1114465108","volume":"108","author":"J Shi","year":"2011","unstructured":"Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA et al (2011) Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 108:17372\u201317377","journal-title":"Proc Natl Acad Sci USA"},{"key":"8918_CR89","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42358-018-0042-8","volume":"59","author":"RS de Brito","year":"2019","unstructured":"de Brito RS, Baldo DC, Andrade LEC (2019) Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol 59:2","journal-title":"Adv Rheumatol"},{"key":"8918_CR90","doi-asserted-by":"crossref","unstructured":"Gr\u00f6nwall C, Liljefors L, Bang H, Hensvold AH, Hansson M, Mathsson-Alm L et al (2021) A comprehensive evaluation of the relationship between different IgG and IgA anti-modified protein autoantibodies in rheumatoid arthritis. Front Immunol 12:627986","DOI":"10.3389\/fimmu.2021.627986"},{"key":"8918_CR91","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"8918_CR92","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/annrheumdis-2017-212365","volume":"77","author":"L Van Hoovels","year":"2018","unstructured":"Van Hoovels L, Jacobs J, Vander Cruyssen B, Van den Bremt S, Verschueren P, Bossuyt X (2018) Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR\/EULAR classification of rheumatoid arthritis. Ann Rheum Dis 77:667\u2013677","journal-title":"Ann Rheum Dis"},{"key":"8918_CR93","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","volume":"146","author":"K Nishimura","year":"2007","unstructured":"Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797\u2013808","journal-title":"Ann Intern Med"},{"key":"8918_CR94","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1172\/JCI1316","volume":"101","author":"GA Schellekens","year":"1998","unstructured":"Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273\u2013281","journal-title":"J Clin Invest"},{"key":"8918_CR95","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","volume":"43","author":"GA Schellekens","year":"2000","unstructured":"Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155\u2013163","journal-title":"Arthritis Rheum"},{"key":"8918_CR96","doi-asserted-by":"publisher","first-page":"R949","DOI":"10.1186\/ar1767","volume":"7","author":"AH van der Helm-van Mil","year":"2005","unstructured":"van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7:R949\u2013R958","journal-title":"Arthritis Res Ther"},{"key":"8918_CR97","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/annrheumdis-2016-209794","volume":"76","author":"VF Derksen","year":"2017","unstructured":"Derksen VF, Ajeganova S, Trouw LA, van der Helm-van Mil AH, Hafstr\u00f6m I, Huizinga TW et al (2017) Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. Ann Rheum Dis 76:716\u2013720","journal-title":"Ann Rheum Dis"},{"key":"8918_CR98","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/annrheumdis-2014-206785","volume":"75","author":"M Juarez","year":"2016","unstructured":"Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I et al (2016) Identification of novel anti-acetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis 75:1099\u20131107","journal-title":"Ann Rheum Dis"},{"key":"8918_CR99","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/1529-0131(200108)44:8<1736::AID-ART308>3.0.CO;2-I","volume":"44","author":"B Combe","year":"2001","unstructured":"Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J et al (2001) Prognostic factors for radiographic damage in early rheumatoid arthritis: a multi parameter prospective study. Arthritis Rheum 44:1736\u20131743","journal-title":"Arthritis Rheum"},{"key":"8918_CR100","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1002\/art.22868","volume":"56","author":"M Bukhari","year":"2007","unstructured":"Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D et al (2007) The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis Rheum 56:2929\u20132935","journal-title":"Arthritis Rheum"},{"key":"8918_CR101","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1136\/ard.2009.121160","volume":"69","author":"K Visser","year":"2010","unstructured":"Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ et al (2010) A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: Post hoc analyses from the BeSt study. Ann Rheum Dis 69:1333\u20131337","journal-title":"Ann Rheum Dis"},{"key":"8918_CR102","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/728610","volume":"2015","author":"AA Jilani","year":"2015","unstructured":"Jilani AA, Mackworth-Young CG (2015) The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis. Int J Rheumatol 2015:728610. https:\/\/doi.org\/10.1155\/2015\/728610","journal-title":"Int J Rheumatol"},{"key":"8918_CR103","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","volume":"373","author":"L Klareskog","year":"2009","unstructured":"Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373:659\u2013672","journal-title":"Lancet"},{"key":"8918_CR104","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/art.1780370511","volume":"37","author":"D Jawaheer","year":"1994","unstructured":"Jawaheer D, Thomson W, MacGregor AJ, Carthy D, Davidson J, Dyer PA et al (1994) Homozygosity for the HLA-DR shared epitope contributes the highest risk for rheumatoid arthritis concordance in identical twins. Arthritis Rheum 37:681\u2013686","journal-title":"Arthritis Rheum"},{"key":"8918_CR105","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3899\/jrheum.131177","volume":"42","author":"RT Alarcon","year":"2015","unstructured":"Alarcon RT, Fernandes AR, Laurindo IM, B\u00e9rtolo MB, Pinheiro GC, Andrade LE (2015) Characterization of cumulative joint damage patterns in patients with rheumatoid arthritis: a clinical, serological, and gene polymorphism perspective. J Rheumatol 42:405\u2013412","journal-title":"J Rheumatol"},{"key":"8918_CR106","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1002\/art.39760","volume":"68","author":"S Viatte","year":"2016","unstructured":"Viatte S, Lee JC, Fu B, Esp\u00e9li M, Lunt M, De Wolf JN et al (2016) Association between genetic variation in FOXO3 and reductions in inflammation and disease activity in inflammatory polyarthritis. Arthritis Rheumatol 68:2629\u20132636","journal-title":"Arthritis Rheumatol"},{"key":"8918_CR107","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/1381612820666140825122525","volume":"21","author":"A Krabben","year":"2015","unstructured":"Krabben A, Huizinga TW, Mil AH (2015) Biomarkers for radiographic progression in rheumatoid arthritis. Curr Pharm Des 21:147\u2013169","journal-title":"Curr Pharm Des"},{"key":"8918_CR108","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2013.08.034","volume":"155","author":"JC Lee","year":"2013","unstructured":"Lee JC, Esp\u00e9li M, Anderson CA, Linterman MA, Pocock JM, Williams NJ et al (2013) Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 155:57\u201369","journal-title":"Cell"},{"key":"8918_CR109","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/annrheumdis-2014-206047","volume":"74","author":"JA van Nies","year":"2015","unstructured":"van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH (2015) Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis 74:806\u2013812","journal-title":"Ann Rheum Dis"},{"key":"8918_CR110","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/art.1780280503","volume":"28","author":"K Aho","year":"1985","unstructured":"Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT (1985) When does rheumatoid disease start? Arthritis Rheum 28:485\u2013489","journal-title":"Arthritis Rheum"},{"key":"8918_CR111","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantap\u00e4\u00e4-Dahlqvist","year":"2003","unstructured":"Rantap\u00e4\u00e4-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741\u20132749","journal-title":"Arthritis Rheum"},{"key":"8918_CR112","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/art.20018","volume":"50","author":"MM Nielen","year":"2004","unstructured":"Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380\u2013386","journal-title":"Arthritis Rheum"},{"key":"8918_CR113","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1136\/annrheumdis-2014-205227","volume":"74","author":"C Rakieh","year":"2015","unstructured":"Rakieh C, Nam JL, Hunt L, Hensor EM, Das S, Bissell LA et al (2015) Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis 74:1659\u20131666","journal-title":"Ann Rheum Dis"},{"key":"8918_CR114","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/ard.2008.105759","volume":"69","author":"WH Bos","year":"2010","unstructured":"Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma IE et al (2010) Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 69:490\u2013494","journal-title":"Ann Rheum Dis"},{"key":"8918_CR115","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/art.40562","volume":"70","author":"MK Verheul","year":"2018","unstructured":"Verheul MK, B\u00f6hringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW et al (2018) Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: Implications for very early identification of at-risk individuals. Arthritis Rheumatol 70:1721\u20131731","journal-title":"Arthritis Rheumatol"},{"key":"8918_CR116","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/annrheumdis-2011-201225","volume":"71","author":"S Viatte","year":"2012","unstructured":"Viatte S, Plant D, Bowes J, Lunt M, Eyre S, Barton A et al (2012) Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann Rheum Dis 71:1984\u20131990","journal-title":"Ann Rheum Dis"},{"key":"8918_CR117","doi-asserted-by":"crossref","unstructured":"Viatte S, Massey J, Bowes J, Duffus K, arcOGEN Consortium, Eyre S et al (2016) Replication of associations of genetic loci outside the HLA region with susceptibility to anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheumatol 68:1603\u20131613","DOI":"10.1002\/art.39619"},{"key":"8918_CR118","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2009.120899","volume":"70","author":"H K\u00e4llberg","year":"2011","unstructured":"K\u00e4llberg H, Ding B, Padyukov L, Bengtsson C, R\u00f6nnelid J, Klareskog L et al (2011) Smoking is a major preventable risk factor for rheumatoid arthritis: Estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 70:508\u2013511","journal-title":"Ann Rheum Dis"},{"key":"8918_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11309","author":"LF Bettner","year":"2021","unstructured":"Bettner LF, Peterson RA, Bergstedt DT, Kelmenson LB, Demoruelle MK, Mikuls TR et al (2021) Combinations of anti-cyclic citrullinated protein antibody, rheumatoid factor, and serum calprotectin positivity are associated with the diagnosis of rheumatoid arthritis within 3 years. ACR Open Rheumatol. https:\/\/doi.org\/10.1002\/acr2.11309","journal-title":"ACR Open Rheumatol"},{"key":"8918_CR120","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13075-020-02190-3","volume":"22","author":"M Jarlborg","year":"2020","unstructured":"Jarlborg M, Courvoisier DS, Lamacchia C, Martinez-Prat L, Mahler M, Bentow C et al (2020) Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther 22:105","journal-title":"Arthritis Res Ther"},{"key":"8918_CR121","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13075-019-2064-y","volume":"21","author":"EC de Moel","year":"2019","unstructured":"de Moel EC, Rech J, Mahler M, Roth J, Vogl T, Schouffoer A et al (2019) Circulating calprotectin (S100A8\/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs. Arthritis Res Ther 21:268","journal-title":"Arthritis Res Ther"},{"key":"8918_CR122","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","volume":"60","author":"DS Courvoisier","year":"2021","unstructured":"Courvoisier DS, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J et al (2021) The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: Results from a collaboration of 16 registries. Rheumatology (Oxford) 60:820\u2013828","journal-title":"Rheumatology (Oxford)"},{"key":"8918_CR123","doi-asserted-by":"crossref","unstructured":"Bird P, Hall S, Nash P, Connell CA, Kwok K, Witcombe D et al (2019) Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in phase III randomised clinical trials of tofacitinib. RMD Open 5:e000742","DOI":"10.1136\/rmdopen-2018-000742"},{"key":"8918_CR124","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/rheumatology\/kez278","volume":"59","author":"L Schlager","year":"2020","unstructured":"Schlager L, Loiskandl M, Aletaha D, Radner H (2020) Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Rheumatology (Oxford) 59:324\u2013334","journal-title":"Rheumatology (Oxford)"},{"key":"8918_CR125","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox RI (2005) Sj\u00f6gren\u2019s syndrome. Lancet 366:321\u2013331","journal-title":"Lancet"},{"key":"8918_CR126","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","volume":"74","author":"B Qin","year":"2015","unstructured":"Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F et al (2015) Epidemiology of primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74:1983\u20131989","journal-title":"Ann Rheum Dis"},{"key":"8918_CR127","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","volume":"42","author":"M Voulgarelis","year":"1999","unstructured":"Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999) Malignant lymphoma in primary Sj\u00f6gren\u2019s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sj\u00f6gren\u2019s Syndrome. Arthritis Rheum 42:1765\u20131772","journal-title":"Arthritis Rheum"},{"key":"8918_CR128","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1586\/1744666X.2014.891439","volume":"10","author":"FG Kroese","year":"2014","unstructured":"Kroese FG, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H (2014) B-cell hyperactivity in primary Sj\u00f6gren\u2019s syndrome. Expert Rev Clin Immunol 10:483\u2013499","journal-title":"Expert Rev Clin Immunol"},{"key":"8918_CR129","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/ard.2004.025676","volume":"64","author":"M Ramos-Casals","year":"2005","unstructured":"Ramos-Casals M, Tzioufas AG, Font J (2005) Primary Sj\u00f6gren\u2019s syndrome: New clinical and therapeutic concepts. Ann Rheum Dis 64:347\u2013354","journal-title":"Ann Rheum Dis"},{"key":"8918_CR130","unstructured":"Brito-Zer\u00f3n P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, Mandl T et al (2018) How immunological profile drives clinical phenotype of primary Sj\u00f6gren\u2019s syndrome at diagnosis: Analysis of 10,500 patients (Sj\u00f6gren Big Data Project). Clin Exp Rheumatol 36(Suppl 112(3)):102\u2013112"},{"issue":"Suppl 118","key":"8918_CR131","first-page":"175","volume":"37","author":"AV Goules","year":"2019","unstructured":"Goules AV, Exarchos TP, Pezoulas VC, Kourou KD, Venetsanopoulou AI, De Vita S et al (2019) Sj\u00f6gren\u2019s syndrome towards precision medicine: the challenge of harmonisation and integration of cohorts. Clin Exp Rheumatol 37(Suppl 118):175\u2013184","journal-title":"Clin Exp Rheumatol"},{"key":"8918_CR132","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1002\/art.39214","volume":"67","author":"E Theander","year":"2015","unstructured":"Theander E, Jonsson R, Sj\u00f6str\u00f6m B, Brokstad K, Olsson P, Henriksson G (2015) Prediction of Sj\u00f6gren\u2019s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol 67:2427\u20132436","journal-title":"Arthritis Rheumatol"},{"key":"8918_CR133","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/art.1780391006","volume":"39","author":"LE Andrade","year":"1996","unstructured":"Andrade LE, Chan EK, Peebles CL, Tan EM (1996) Two major autoantigen-antibody systems of the mitotic spindle apparatus. Arthritis Rheum 39:1643\u20131653","journal-title":"Arthritis Rheum"},{"key":"8918_CR134","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","volume":"76","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM et al (2017) 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 76:9\u201316","journal-title":"Ann Rheum Dis"},{"key":"8918_CR135","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/art.1780190214","volume":"19","author":"MA Alspaugh","year":"1976","unstructured":"Alspaugh MA, Talal N, Tan EM (1976) Differentiation and characterization of autoantibodies and their antigens in Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 19:216\u2013222","journal-title":"Arthritis Rheum"},{"key":"8918_CR136","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.autrev.2005.10.004","volume":"5","author":"SL Wolin","year":"2006","unstructured":"Wolin SL, Reinisch KM (2006) The Ro 60 kDa autoantigen comes into focus: Interpreting epitope mapping experiments on the basis of structure. Autoimmun Rev 5:367\u2013372","journal-title":"Autoimmun Rev"},{"key":"8918_CR137","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2012.01.014","volume":"39","author":"V Oke","year":"2012","unstructured":"Oke V, Wahren-Herlenius M (2012) The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 39:77\u201382","journal-title":"J Autoimmun"},{"key":"8918_CR138","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/ket295","volume":"52","author":"A Mekinian","year":"2013","unstructured":"Mekinian A, Nicaise-Roland P, Chollet-Martin S, Fain O, Crestani B (2013) Anti-SSA Ro52\/Ro60 antibody testing by immunodot could help the diagnosis of Sjogren\u2019s syndrome in the absence of anti-SSA\/SSB antibodies by ELISA. Rheumatology (Oxford) 52:2223\u20132228","journal-title":"Rheumatology (Oxford)"},{"key":"8918_CR139","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fimmu.2019.00444","volume":"10","author":"A Robbins","year":"2019","unstructured":"Robbins A, Hentzien M, Toquet S, Didier K, Servettaz A, Pham BN et al (2019) Diagnostic utility of separate anti-Ro60 and anti-Ro52\/TRIM21 antibody detection in autoimmune diseases. Front Immunol 10:444. https:\/\/doi.org\/10.3389\/fimmu.2019.00444","journal-title":"Front Immunol"},{"key":"8918_CR140","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.autrev.2011.03.004","volume":"10","author":"P Ghillani","year":"2011","unstructured":"Ghillani P, Andr\u00e9 C, Toly C, Rouquette AM, Bengoufa D, Nicaise P et al (2011) Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: Results of a multicentric study. Autoimmun Rev 10:509\u2013513","journal-title":"Autoimmun Rev"},{"key":"8918_CR141","first-page":"686","volume":"30","author":"S Retamozo","year":"2012","unstructured":"Retamozo S, Akasbi M, Brito-Zer\u00f3n P, Bosch X, Bove A, Perez-de-Lis M et al (2012) Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol 30:686\u2013692","journal-title":"Clin Exp Rheumatol"},{"key":"8918_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105895","volume":"163","author":"C Buvry","year":"2020","unstructured":"Buvry C, Cassagnes L, Tekath M, Artigues M, Pereira B, Rieu V et al (2020) Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sj\u00f6gren syndrome. Respir Med 163:105895. https:\/\/doi.org\/10.1016\/j.rmed.2020.105895","journal-title":"Respir Med"},{"key":"8918_CR143","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.autrev.2015.07.002","volume":"14","author":"L Quartuccio","year":"2015","unstructured":"Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L et al (2015) Anti-SSA\/SSB-negative Sj\u00f6gren\u2019s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev 14:1019\u20131022","journal-title":"Autoimmun Rev"},{"key":"8918_CR144","first-page":"349","volume":"32","author":"EJ ter Borg","year":"2014","unstructured":"ter Borg EJ, Kelder JC (2014) Lower prevalence of extra-glandular manifestations and anti-SSB antibodies in patients with primary Sj\u00f6gren\u2019s syndrome and widespread pain: Evidence for a relatively benign subset. Clin Exp Rheumatol 32:349\u2013353","journal-title":"Clin Exp Rheumatol"},{"key":"8918_CR145","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1136\/annrheumdis-2014-206683","volume":"74","author":"AN Baer","year":"2015","unstructured":"Baer AN, McAdams DeMarco M, Shiboski SC, Lam MY, Challacombe S, Daniels TE et al (2015) The SSB-positive\/SSA-negative antibody profile is not associated with key phenotypic features of Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 74:1557\u20131561","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 126","key":"8918_CR146","first-page":"85","volume":"38","author":"N Acar-Denizli","year":"2020","unstructured":"Acar-Denizli N, Horv\u00e1th IF, Mandl T, Priori R, Vissink A, Hernandez-Molina G et al (2020) Systemic phenotype related to primary Sj\u00f6gren\u2019s syndrome in 279 patients carrying isolated anti-La\/SSB antibodies. Clin Exp Rheumatol 38(Suppl 126):85\u201394","journal-title":"Clin Exp Rheumatol"},{"key":"8918_CR147","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/acr.22859","volume":"68","author":"AN Baer","year":"2016","unstructured":"Baer AN, Medrano L, McAdams-DeMarco M, Gniadek TJ (2016) Association of anticentromere antibodies with more severe exocrine glandular dysfunction in Sj\u00f6gren\u2019s syndrome: Analysis of the Sj\u00f6gren\u2019s International Collaborative Clinical Alliance Cohort. Arthritis Care Res (Hoboken) 68:1554\u20131559","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8918_CR148","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00296-012-2572-4","volume":"33","author":"YS Ryu","year":"2013","unstructured":"Ryu YS, Park SH, Lee J, Kwok SK, Ju JH, Kim HY et al (2013) Follow-up of primary Sjogren\u2019s syndrome patients presenting positive anti-cyclic citrullinated peptides antibody. Rheumatol Int 33:1443\u20131446","journal-title":"Rheumatol Int"},{"key":"8918_CR149","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0140-6736(11)60242-0","volume":"379","author":"M Ramos-Casals","year":"2012","unstructured":"Ramos-Casals M, Stone JH, Cid MC, Bosch X (2012) The cryoglobulinaemias. Lancet 379:348\u2013360","journal-title":"Lancet"},{"key":"8918_CR150","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/art.1780381222","volume":"38","author":"L La Civita","year":"1995","unstructured":"La Civita L, Zignego AL, Monti M, Longombardo G, Pasero G, Ferri C (1995) Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum 38:1859\u20131860","journal-title":"Arthritis Rheum"},{"key":"8918_CR151","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2014-206418","volume":"75","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n P, Kostov B, Solans R, Fraile G, Su\u00e1rez-Cuervo C, Casanovas A et al (2016) Systemic activity and mortality in primary Sj\u00f6gren syndrome: Predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 75:348\u2013355","journal-title":"Ann Rheum Dis"},{"key":"8918_CR152","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jaut.2013.10.002","volume":"51","author":"L Quartuccio","year":"2014","unstructured":"Quartuccio L, Isola M, Baldini C, Priori R, Bocci EB, Carubbi F et al (2014) Biomarkers of lymphoma in Sj\u00f6gren\u2019s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 51:75\u201380","journal-title":"J Autoimmun"},{"key":"8918_CR153","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5114\/reum.2020.102000","volume":"58","author":"M Legatowicz-Koprowska","year":"2020","unstructured":"Legatowicz-Koprowska M, Nitek S, Czerwi\u0144ska J (2020) The complement system in primary Sj\u00f6gren\u2019s syndrome: The expression of certain cascade and regulatory proteins in labial salivary glands \u2013 observational study. Reumatologia 58:357\u2013366","journal-title":"Reumatologia"},{"key":"8918_CR154","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MD.0b013e3181b76ab5","volume":"88","author":"E Baimpa","year":"2009","unstructured":"Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sj\u00f6gren syndrome: Clinical and pathophysiologic aspects. Medicine (Baltimore) 88:284\u2013293","journal-title":"Medicine (Baltimore)"},{"key":"8918_CR155","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaut.2012.01.010","volume":"39","author":"P Brito-Zer\u00f3n","year":"2012","unstructured":"Brito-Zer\u00f3n P, Retamozo S, Gand\u00eda M, Akasbi M, P\u00e9rez-De-Lis M, Diaz-Lagares C et al (2012) Monoclonal gammopathy related to Sj\u00f6gren syndrome: a key marker of disease prognosis and outcomes. J Autoimmun 39:43\u201348","journal-title":"J Autoimmun"},{"key":"8918_CR156","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390:1685\u20131699","journal-title":"Lancet"},{"key":"8918_CR157","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.semarthrit.2007.05.003","volume":"37","author":"H Chifflot","year":"2008","unstructured":"Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J (2008) Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 37:223\u2013235","journal-title":"Semin Arthritis Rheum"},{"key":"8918_CR158","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0889-857X(03)00023-1","volume":"29","author":"TA Medsger Jr","year":"2003","unstructured":"Medsger TA Jr (2003) Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 29:255\u2013273","journal-title":"Rheum Dis Clin North Am"},{"key":"8918_CR159","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","volume":"35","author":"VD Steen","year":"2005","unstructured":"Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35\u201342","journal-title":"Semin Arthritis Rheum"},{"key":"8918_CR160","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fimmu.2015.00167","volume":"6","author":"C Kayser","year":"2015","unstructured":"Kayser C, Fritzler MJ (2015) Autoantibodies in systemic sclerosis: Unanswered questions. Front Immunol 6:167","journal-title":"Front Immunol"},{"key":"8918_CR161","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","volume":"12","author":"S Mehra","year":"2013","unstructured":"Mehra S, Walker J, Patterson K, Fritzler MJ (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12:340\u2013354","journal-title":"Autoimmun Rev"},{"key":"8918_CR162","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s13317-017-0098-1","volume":"8","author":"S Sirotti","year":"2017","unstructured":"Sirotti S, Generali E, Ceribelli A, Isailovic N, De Santis M, Selmi C (2017) Personalized medicine in rheumatology: The paradigm of serum autoantibodies. Autoimmun Highlights 8:10","journal-title":"Autoimmun Highlights"},{"key":"8918_CR163","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirj\u00e1k L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 66:754\u2013763","journal-title":"Ann Rheum Dis"},{"key":"8918_CR164","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/art.10977","volume":"48","author":"PQ Hu","year":"2003","unstructured":"Hu PQ, Fertig N, Medsger TA Jr, Wright TM (2003) Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48:1363\u20131373","journal-title":"Arthritis Rheum"},{"key":"8918_CR165","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.1780370111","volume":"37","author":"M Kuwana","year":"1994","unstructured":"Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75\u201383","journal-title":"Arthritis Rheum"},{"key":"8918_CR166","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/art.39022","volume":"67","author":"AA Shah","year":"2015","unstructured":"Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM (2015) Examination of autoantibody status and clinical features associated with cancer risk and cancer associated scleroderma. Arthritis Rheumatol 67:1053\u20131061","journal-title":"Arthritis Rheumatol"},{"key":"8918_CR167","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/BOR.0000000000000711","volume":"32","author":"D Roofeh","year":"2020","unstructured":"Roofeh D, Khanna D (2020) Management of systemic sclerosis: The first five years. Curr Opin Rheumatol 32:228\u2013237","journal-title":"Curr Opin Rheumatol"},{"key":"8918_CR168","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/08923973.2012.733707","volume":"35","author":"A Saito","year":"2013","unstructured":"Saito A, Muro Y, Sugiura K, Akiyama M (2013) Low prevalence of autoantibodies to CENP-H, -I, -K, -L, -M, -N, -T and -U in a Japanese cohort of anti-centromere positive samples. Immunopharmacol Immunotoxicol 35:57\u201363","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"8918_CR169","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1002\/art.39316","volume":"67","author":"KA Patterson","year":"2015","unstructured":"Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M et al (2015) Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis. Arthritis Rheumatol 67:3234\u20133244","journal-title":"Arthritis Rheumatol"},{"key":"8918_CR170","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/ard.47.8.634","volume":"47","author":"CG Kallenberg","year":"1988","unstructured":"Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ (1988) Development of connective tissue disease in patients presenting with Raynaud\u2019s phenomenon: a six-year follow-up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 47:634\u2013641","journal-title":"Ann Rheum Dis"},{"key":"8918_CR171","first-page":"2253","volume":"34","author":"C Salliot","year":"2007","unstructured":"Salliot C, Gottenberg JE, Bengoufa D, Desmoulins F, Miceli-Richard C, Mariette X (2007) Anti-centromere antibodies identify patients with Sj\u00f6gren\u2019s syndrome and autoimmune overlap syndrome. J Rheumatol 34:2253\u20132258","journal-title":"J Rheumatol"},{"key":"8918_CR172","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/art.38994","volume":"67","author":"Y Hamaguchi","year":"2015","unstructured":"Hamaguchi Y, Kodera M, Matsushita T, Hasegawa M, Inaba Y, Usuda T et al (2015) Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol 67:1045\u20131052","journal-title":"Arthritis Rheumatol"},{"key":"8918_CR173","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3899\/jrheum.160817","volume":"44","author":"MG Lazzaroni","year":"2017","unstructured":"Lazzaroni MG, Cavazzana I, Colombo E, Dobrota R, Hernandez J, Hesselstrand R et al (2017) Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: Analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening. J Rheumatol 44:639\u2013647","journal-title":"J Rheumatol"},{"key":"8918_CR174","first-page":"2489","volume":"26","author":"TG Phan","year":"1999","unstructured":"Phan TG, Cass A, Gillin A, Trew P, Fertig N, Sturgess A (1999) Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis sine scleroderma. J Rheumatol 26:2489\u20132492","journal-title":"J Rheumatol"},{"key":"8918_CR175","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3899\/jrheum.100124","volume":"37","author":"A Ceribelli","year":"2010","unstructured":"Ceribelli A, Cavazzana I, Airo P, Franceschini F (2010) Anti-RNA polymerase III antibodies as a risk marker for early gastric antral vascular ectasia (GAVE) in systemic sclerosis. J Rheumatol 37:1544","journal-title":"J Rheumatol"},{"key":"8918_CR176","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.3899\/jrheum.110071","volume":"38","author":"R Sharif","year":"2011","unstructured":"Sharif R, Fritzler MJ, Mayes MD, Gonzalez EB, McNearney TA, Draeger H et al (2011) Anti-fibrillarin antibody in African American patients with systemic sclerosis: Immunogenetics, clinical features, and survival analysis. J Rheumatol 38:1622\u20131630","journal-title":"J Rheumatol"},{"key":"8918_CR177","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.24409","volume":"60","author":"R Aggarwal","year":"2009","unstructured":"Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr (2009) Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 60:1112\u20131118","journal-title":"Arthritis Rheum"},{"key":"8918_CR178","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/art.10760","volume":"48","author":"GM Mitri","year":"2003","unstructured":"Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr (2003) A comparison between anti-Th\/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 48:203\u2013209","journal-title":"Arthritis Rheum"},{"key":"8918_CR179","first-page":"1600","volume":"33","author":"A Fischer","year":"2006","unstructured":"Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, Wright TM, Curran-Everett D, West SG et al (2006) Anti-Th\/To-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 33:1600\u20131605","journal-title":"J Rheumatol"},{"key":"8918_CR180","doi-asserted-by":"publisher","first-page":"R50","DOI":"10.1186\/ar3763","volume":"14","author":"M Hudson","year":"2012","unstructured":"Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M et al (2012) Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis. Arthritis Res Ther 14:R50","journal-title":"Arthritis Res Ther"},{"key":"8918_CR181","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/art.24586","volume":"61","author":"N Fertig","year":"2009","unstructured":"Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger TA Jr et al (2009) Anti-U11\/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 61:958\u2013965","journal-title":"Arthritis Rheum"},{"key":"8918_CR182","doi-asserted-by":"publisher","first-page":"R172","DOI":"10.1186\/ar3495","volume":"13","author":"R Mierau","year":"2011","unstructured":"Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F et al (2011) Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: Correlation with characteristic clinical features. Arthritis Res Ther 13:R172","journal-title":"Arthritis Res Ther"},{"key":"8918_CR183","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13075-015-0573-x","volume":"17","author":"Y Muro","year":"2015","unstructured":"Muro Y, Hosono Y, Sugiura K, Ogawa Y, Mimori T, Akiyama M (2015) Anti-PM\/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ther 17:57","journal-title":"Arthritis Res Ther"},{"key":"8918_CR184","doi-asserted-by":"crossref","unstructured":"Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W et al (2016) Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: Clinical associations. Medicine (Baltimore) 95:e4713","DOI":"10.1097\/MD.0000000000004713"},{"key":"8918_CR185","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/art.1780390808","volume":"39","author":"T Fujii","year":"1996","unstructured":"Fujii T, Mimori T, Akizuki M (1996) Detection of autoantibodies to nucleolar transcription factor NOR 90\/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Arthritis Rheum 39:1313\u20131318","journal-title":"Arthritis Rheum"},{"key":"8918_CR186","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347","journal-title":"N Engl J Med"},{"key":"8918_CR187","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403\u2013407","journal-title":"N Engl J Med"},{"key":"8918_CR188","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","volume":"75","author":"K Mariampillai","year":"2018","unstructured":"Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F et al (2018) Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 75:1528\u20131537","journal-title":"JAMA Neurol"},{"key":"8918_CR189","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/WCO.0000000000000855","volume":"33","author":"J Tanboon","year":"2020","unstructured":"Tanboon J, Uruha A, Stenzel W, Nishino I (2020) Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opin Neurol 33:590\u2013603","journal-title":"Curr Opin Neurol"},{"key":"8918_CR190","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","volume":"54","author":"A Meyer","year":"2015","unstructured":"Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J (2015) Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 54:50\u201363","journal-title":"Rheumatology (Oxford)"},{"key":"8918_CR191","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/BOR.0000000000000742","volume":"32","author":"V Riddell","year":"2020","unstructured":"Riddell V, Bagby S, McHugh N (2020) Myositis autoantibodies: recent perspectives. Curr Opin Rheumatol 32:548\u2013552","journal-title":"Curr Opin Rheumatol"},{"key":"8918_CR192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","volume":"52","author":"M Satoh","year":"2017","unstructured":"Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL (2017) Comprehensive overview on myositis-specific antibodies: New and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52:1\u201319","journal-title":"Clin Rev Allergy Immunol"},{"key":"8918_CR193","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","volume":"13","author":"M Mahler","year":"2014","unstructured":"Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13:367\u2013371","journal-title":"Autoimmun Rev"},{"key":"8918_CR194","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/ard.60.2.116","volume":"60","author":"R Brouwer","year":"2001","unstructured":"Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A et al (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60:116\u2013123","journal-title":"Ann Rheum Dis"},{"key":"8918_CR195","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","volume":"73","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP et al (2014) Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73:227\u2013232","journal-title":"Ann Rheum Dis"},{"key":"8918_CR196","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrneurol.2011.63","volume":"7","author":"AL Mammen","year":"2011","unstructured":"Mammen AL (2011) Autoimmune myopathies: Autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 7:343\u2013354","journal-title":"Nat Rev Neurol"},{"key":"8918_CR197","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.3390\/jcm10081725","volume":"10","author":"N Okiyama","year":"2021","unstructured":"Okiyama N (2021) Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies. J Clin Med 10:1725","journal-title":"J Clin Med"},{"key":"8918_CR198","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.33403","volume":"64","author":"M Fujimoto","year":"2012","unstructured":"Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M et al (2012) Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64:513\u2013522","journal-title":"Arthritis Rheum"},{"key":"8918_CR199","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12948-018-0084-9","volume":"16","author":"B Palterer","year":"2018","unstructured":"Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, Parronchi P (2018) Bench to bedside review of myositis autoantibodies. Clin Mol Allergy 16:5\u201322","journal-title":"Clin Mol Allergy"},{"key":"8918_CR200","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","volume":"51","author":"T Koga","year":"2012","unstructured":"Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N et al (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 51:1278\u20131284","journal-title":"Rheumatology (Oxford)"},{"key":"8918_CR201","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65:25\u201334","journal-title":"J Am Acad Dermatol"},{"key":"8918_CR202","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1002\/art.22862","volume":"56","author":"Z Betteridge","year":"2007","unstructured":"Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N (2007) Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 56:3132\u20133137","journal-title":"Arthritis Rheum"},{"key":"8918_CR203","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11926-015-0548-6","volume":"17","author":"P Basharat","year":"2015","unstructured":"Basharat P, Christopher-Stine L (2015) Immune-mediated necrotizing myopathy: Update on diagnosis and management. Curr Rheumatol Rep 17:72","journal-title":"Curr Rheumatol Rep"},{"key":"8918_CR204","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ana.23822","volume":"73","author":"H Pluk","year":"2013","unstructured":"Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ et al (2013) Autoantibodies to cytosolic 5\u2019-nucleotidase 1A in inclusion body myositis. Ann Neurol 73:397\u2013407","journal-title":"Ann Neurol"},{"key":"8918_CR205","doi-asserted-by":"crossref","unstructured":"Amlani A, Choi MY, Tarnopolsky M, Brady L, Clarke AE, Garcia-De La Torre I et al (2019) Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis. Front Immunol 10:745","DOI":"10.3389\/fimmu.2019.00745"},{"key":"8918_CR206","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","volume":"75","author":"MK Herbert","year":"2016","unstructured":"Herbert MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, Lundberg IE, Chinoy H et al (2016) Disease specificity of autoantibodies to cytosolic 5\u2019-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 75:696\u2013701","journal-title":"Ann Rheum Dis"},{"key":"8918_CR207","doi-asserted-by":"crossref","unstructured":"Rietveld A, Wienke J, Visser E, Vree Egberts W, Schlumberger W, van Engelen B et al (2021) Juvenile Dermatomyositis Research Group and the Dutch Myositis Consortium. Anti-Cytosolic 5'-nucleotidase 1A autoantibodies are absent in juvenile dermatomyositis. Arthritis Rheumatol 73:1329\u20131333","DOI":"10.1002\/art.41660"},{"key":"8918_CR208","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"European Association for the Study of the Liver","year":"2015","unstructured":"European Association for the Study of the Liver (2015) EASL clinical practice guidelines: Autoimmune hepatitis. J Hepatol 63:971\u20131004","journal-title":"J Hepatol"},{"key":"8918_CR209","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67:145\u2013172","journal-title":"J Hepatol"},{"key":"8918_CR210","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ et al (2009) Primary biliary cirrhosis. Hepatology 50:291\u2013308","journal-title":"Hepatology"},{"key":"8918_CR211","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jhep.2015.03.005","volume":"62","author":"MP Manns","year":"2015","unstructured":"Manns MP, Lohse AW, Vergani D (2015) Autoimmune hepatitis \u2013 update 2015. J Hepatol 62:100\u2013111","journal-title":"J Hepatol"},{"key":"8918_CR212","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","volume":"9","author":"M Sebode","year":"2018","unstructured":"Sebode M, Weiler-Normann C, Liwinski T, Schramm C (2018) Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol 9:609","journal-title":"Front Immunol"},{"key":"8918_CR213","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/hep.510250308","volume":"25","author":"GV Gregorio","year":"1997","unstructured":"Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M et al (1997) Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 25:541\u2013547","journal-title":"Hepatology"},{"key":"8918_CR214","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.1840070626","volume":"7","author":"JC Homberg","year":"1987","unstructured":"Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH et al (1987) Chronic active hepatitis associated with anti-liver\/kidney microsome antibody type 1: a second type of autoimmune hepatitis. Hepatology 7:1333\u20131339","journal-title":"Hepatology"},{"key":"8918_CR215","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/hep.1840080632","volume":"8","author":"E Martini","year":"1988","unstructured":"Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC (1988) Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 8:1662\u20131666","journal-title":"Hepatology"},{"key":"8918_CR216","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/01.mcg.0000139072.38580.a0","volume":"38","author":"SJ Cotler","year":"2004","unstructured":"Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S (2004) Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol 38:801\u2013804","journal-title":"J Clin Gastroenterol"},{"key":"8918_CR217","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","volume":"41","author":"D Vergani","year":"2004","unstructured":"Vergani D, Alvarez F, Bianchi FB, Can\u00e7ado EL, Mackay IR, Manns MP et al (2004) Liver autoimmune serology: a consensus statement from the Committee for Autoimmune Serology of the International Autoimmune Hepatitis Group. J Hepatol 41:677\u2013683","journal-title":"J Hepatol"},{"key":"8918_CR218","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1111\/j.1572-0241.2006.00830.x","volume":"101","author":"C Frenzel","year":"2006","unstructured":"Frenzel C, Herkel J, L\u00fcth S, Galle PR, Schramm C, Lohse AW (2006) Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol 101:2731\u20132736","journal-title":"Am J Gastroenterol"},{"key":"8918_CR219","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/jcp.2006.039404","volume":"60","author":"C Liaskos","year":"2007","unstructured":"Liaskos C, Bogdanos DP, Davies ET, Dalekos GN (2007) Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. J Clin Pathol 60:107\u2013108","journal-title":"J Clin Pathol"},{"key":"8918_CR220","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1046\/j.1365-2249.2001.01649.x","volume":"126","author":"B Terjung","year":"2001","unstructured":"Terjung B, Worman HJ, Herzog V, Sauerbruch T, Spengler U (2001) Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol 126:37\u201346","journal-title":"Clin Exp Immunol"},{"key":"8918_CR221","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1084\/jem.168.2.801","volume":"168","author":"M Gueguen","year":"1988","unstructured":"Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F (1988) Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 168:801\u2013806","journal-title":"J Exp Med"},{"key":"8918_CR222","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1172\/JCI113949","volume":"83","author":"MP Manns","year":"1989","unstructured":"Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF (1989) Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 83:1066\u20131072","journal-title":"J Clin Invest"},{"key":"8918_CR223","doi-asserted-by":"publisher","first-page":"8256","DOI":"10.1073\/pnas.85.21.8256","volume":"85","author":"UM Zanger","year":"1988","unstructured":"Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA (1988) Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 85:8256\u20138260","journal-title":"Proc Natl Acad Sci USA"},{"key":"8918_CR224","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0016-5085(99)70186-1","volume":"116","author":"P Lapierre","year":"1999","unstructured":"Lapierre P, Hajoui O, Homberg JC, Alvarez F (1999) Formiminotransferase cyclo-deaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 116:643\u2013649","journal-title":"Gastroenterology"},{"key":"8918_CR225","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.36.5.749","volume":"36","author":"M Lenzi","year":"1995","unstructured":"Lenzi M, Manotti P, Muratori L, Cataleta M, Ballardini G, Cassani F et al (1995) Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 36:749\u2013754","journal-title":"Gut"},{"key":"8918_CR226","doi-asserted-by":"crossref","unstructured":"Kanzler S, Weidemann C, Gerken G, L\u00f6hr HF, Galle PR, zum B\u00fcschenfelde KHM et al (1999) Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 31:635\u2013640","DOI":"10.1016\/S0168-8278(99)80342-0"},{"key":"8918_CR227","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/hep.27983","volume":"62","author":"MM Kirstein","year":"2015","unstructured":"Kirstein MM, Metzler F, Geiger E, Heinrich E, Hallensleben M, Manns MP et al (2015) Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 62:1524\u20131535","journal-title":"Hepatology"},{"key":"8918_CR228","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1478-3231.2011.02502.x","volume":"32","author":"AJ Montano-Loza","year":"2012","unstructured":"Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ (2012) Prognostic implications of antibodies to Ro\/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 32:85\u201392","journal-title":"Liver Int"},{"key":"8918_CR229","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.autrev.2012.04.005","volume":"12","author":"EI Rigopoulou","year":"2012","unstructured":"Rigopoulou EI, Roggenbuck D, Smyk DS, Liaskos C, Mytilinaiou MG, Feist E et al (2012) Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: Lost and found. Autoimmun Rev 12:260\u2013269","journal-title":"Autoimmun Rev"},{"key":"8918_CR230","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaut.2013.08.001","volume":"46","author":"R Liberal","year":"2013","unstructured":"Liberal R, Mieli-Vergani G, Vergani D (2013) Clinical significance of autoantibodies in autoimmune hepatitis. J Autoimmun 46:17\u201324","journal-title":"J Autoimmun"},{"key":"8918_CR231","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.autrev.2015.10.007","volume":"15","author":"C Selmi","year":"2016","unstructured":"Selmi C, Ceribelli A, Generali E, Scir\u00e8 CA, Alborghetti F, Colloredo G et al (2016) Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun Rev 15:162\u2013166","journal-title":"Autoimmun Rev"},{"key":"8918_CR232","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/art.34380","volume":"64","author":"M Satoh","year":"2012","unstructured":"Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD et al (2012) Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 64:2319\u20132327","journal-title":"Arthritis Rheum"},{"key":"8918_CR233","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0961203319838348","volume":"28","author":"RA Agustinelli","year":"2019","unstructured":"Agustinelli RA, Rodrigues SH, Mariz HA, Prado MS, Andrade LEC (2019) Distinctive features of positive anti-cell antibody tests (indirect immunofluorescence on HEp-2 cells) in patients with non-autoimmune diseases. Lupus 28:629\u2013634","journal-title":"Lupus"},{"key":"8918_CR234","doi-asserted-by":"crossref","unstructured":"Keppeke GD, Nunes E, Ferraz ML, Silva EA, Granato C, Chan EK et al (2012) Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods\/rings following HCV therapy with ribavirin and interferon-\u03b1. PLoS One 7:e45392","DOI":"10.1371\/journal.pone.0045392"},{"key":"8918_CR235","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s10875-012-9827-4","volume":"33","author":"WC Carcamo","year":"2013","unstructured":"Carcamo WC, Ceribelli A, Calise SJ, Krueger C, Chen L, Daves M et al (2013) Differential reactivity to IMPDH2 by anti-rods\/rings autoantibodies and unresponsiveness to pegylated interferon-alpha\/ribavirin therapy in US and Italian HCV patients. J Clin Immunol 33:420\u2013426","journal-title":"J Clin Immunol"},{"key":"8918_CR236","doi-asserted-by":"crossref","unstructured":"Calise SJ, Chan EKL (2020) Anti-rods\/rings autoantibody and IMPDH filaments: an update after fifteen years of discovery. Autoimmun Rev19:102643","DOI":"10.1016\/j.autrev.2020.102643"},{"key":"8918_CR237","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/hep.1840190629","volume":"19","author":"VJ Desmet","year":"1994","unstructured":"Desmet VJ, Gerber M, Hoofnaagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513\u20131520","journal-title":"Hepatology"},{"key":"8918_CR238","doi-asserted-by":"crossref","unstructured":"Manns M, Gerken G, Kyriatsoulis A, Staritz M, zum Buschenfelde KHM (1987) Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1:292\u2013294","DOI":"10.1016\/S0140-6736(87)92024-1"},{"key":"8918_CR239","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/gut.51.2.259","volume":"51","author":"M Baeres","year":"2002","unstructured":"Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL et al (2002) Establishment of standardised SLA\/LP immunoassays: Specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 51:259\u2013264","journal-title":"Gut"},{"key":"8918_CR240","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/0016-5085(93)90157-8","volume":"105","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA, Santrach PJ, Moore SB (1993) Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105:1502\u20131507","journal-title":"Gastroenterology"},{"key":"8918_CR241","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/hep.22380","volume":"48","author":"C O\u2019Brien","year":"2008","unstructured":"O\u2019Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ (2008) Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 48:550\u2013556","journal-title":"Hepatology"},{"key":"8918_CR242","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cgh.2012.02.010","volume":"10","author":"AM Dinani","year":"2012","unstructured":"Dinani AM, Fischer SE, Mosko J, Guindi M, Hirschfield GM (2012) Patients with autoimmune hepatitis who have antimitochondrial antibodies need longterm follow-up to detect late development of primary biliary cirrhosis. Clin Gastroenterol Hepatol 10:682\u2013684","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8918_CR243","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/hep.21828","volume":"46","author":"PS Leung","year":"2007","unstructured":"Leung PS, Rossaro L, Davis PA, Park O, Tanaka A, Kikuchi K et al (2007) Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis. Hepatology 46:1436\u20131442","journal-title":"Hepatology"},{"key":"8918_CR244","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/j.1478-3231.2007.01586.x","volume":"27","author":"EI Rigopoulou","year":"2007","unstructured":"Rigopoulou EI, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK et al (2007) Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 27:1226\u20131231","journal-title":"Liver Int"},{"key":"8918_CR245","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot C, Chazouilleres O, Poupon R (2011) Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 55:1361\u20131367","journal-title":"J Hepatol"},{"key":"8918_CR246","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1046\/j.1365-2249.2002.01719.x","volume":"127","author":"P Muratori","year":"2002","unstructured":"Muratori P, Muratori L, Cassani F, Terlizzi P, Lenzi M, Rodrigo L et al (2002) Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol 127:172\u2013175","journal-title":"Clin Exp Immunol"},{"key":"8918_CR247","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1006\/excr.1996.0368","volume":"229","author":"C Andre","year":"1996","unstructured":"Andre C, Guillemin MC, Zhu J, Koken MH, Quignon F, Herve L et al (1996) The PML and PML\/RARalpha domains: From autoimmunity to molecular oncology and from retinoic acid to arsenic. Exp Cell Res 229:253\u2013260","journal-title":"Exp Cell Res"},{"key":"8918_CR248","first-page":"1123","volume":"26","author":"D Zuchner","year":"1997","unstructured":"Zuchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H (1997) Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 26:1123\u20131130","journal-title":"Hepatology"},{"key":"8918_CR249","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1007\/s10620-010-1268-4","volume":"55","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ (2010) Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 55:2144\u20132161","journal-title":"Dig Dis Sci"},{"key":"8918_CR250","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hep.21472","volume":"45","author":"M Nakamura","year":"2007","unstructured":"Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M et al (2007) Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45:118\u2013127","journal-title":"Hepatology"},{"key":"8918_CR251","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.3748\/wjg.v16.i39.4938","volume":"16","author":"O Sfakianaki","year":"2010","unstructured":"Sfakianaki O, Koulentaki M, Tzardi M, Tsangaridou E, Theodoropoulos PA, Castanas E et al (2010) Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients. World J Gastroenterol 16:4938\u20134943","journal-title":"World J Gastroenterol"},{"key":"8918_CR252","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.clinre.2013.04.005","volume":"37","author":"R Liberal","year":"2013","unstructured":"Liberal R, Grant CR, Sakkas L, Bizzaro N, Bogdanos DP (2013) Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clin Res Hepatol Gastroenterol 37:572\u2013585","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"8918_CR253","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3389\/fimmu.2019.00662","volume":"10","author":"GL Norman","year":"2019","unstructured":"Norman GL, Reig A, Vi\u00f1as O, Mahler M, Wunsch E, Milkiewicz P et al (2019) The prevalence of anti-hexokinase-1 and anti-Kelch-like 12 peptide antibodies in patients with primary biliary cholangitis is similar in Europe and North America: a large international, multi-center study. Front Immunol 10:662","journal-title":"Front Immunol"},{"issue":"Suppl 2","key":"8918_CR254","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000440831","volume":"33","author":"O Chazouill\u00e8res","year":"2015","unstructured":"Chazouill\u00e8res O (2015) Overlap syndromes. Dig Dis Basel Switz 33(Suppl 2):181\u2013187","journal-title":"Dig Dis Basel Switz"},{"key":"8918_CR255","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","volume":"102","author":"MG Silveira","year":"2007","unstructured":"Silveira MG, Talwalkar JA, Angulo P, Lindor KD (2007) Overlap of autoimmune hepatitis and primary biliary cirrhosis: Long-term outcomes. Am J Gastroenterol 102:1244\u20131250","journal-title":"Am J Gastroenterol"},{"key":"8918_CR256","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.510280203","volume":"28","author":"O Chazouill\u00e8res","year":"1998","unstructured":"Chazouill\u00e8res O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R (1998) Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatol Baltim Md 28:296\u2013301","journal-title":"Hepatol Baltim Md"},{"key":"8918_CR257","doi-asserted-by":"crossref","unstructured":"Nguyen HH, Shaheen AA, Baeza N, Lytvyak F, Urbanski SJ, Mason AL et al (2018) Evaluation of classical and novel autoantibodies for the diagnosis of primary biliary cholangitis\u2013autoimmune hepatitis overlap syndrome (PBC-AIH OS). PLoS One 13:e0193960","DOI":"10.1371\/journal.pone.0193960"},{"key":"8918_CR258","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/ajg.2009.126","volume":"104","author":"P Muratori","year":"2009","unstructured":"Muratori P, Granito A, Pappas G, Pendino GM, Quarneti C, Cicola R et al (2009) The serological profile of the autoimmune hepatitis\/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 104:1420\u20131425","journal-title":"Am J Gastroenterol"},{"key":"8918_CR259","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1155\/2012\/890698","volume":"26","author":"T Himoto","year":"2012","unstructured":"Himoto T, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F et al (2012) Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases. Can J Gastroenterol 26:125\u2013129","journal-title":"Can J Gastroenterol"},{"key":"8918_CR260","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00206","volume":"6","author":"R H\u00f6ftberger","year":"2015","unstructured":"H\u00f6ftberger R (2015) Neuroimmunology: an expanding frontier in autoimmunity. Front Immunol 6:1\u20135","journal-title":"Front Immunol"},{"key":"8918_CR261","first-page":"815","volume":"25","author":"EP Flanagan","year":"2019","unstructured":"Flanagan EP (2019) Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases. Continuum (Minneap Minn) 25:815\u2013844","journal-title":"Continuum (Minneap Minn)"},{"key":"8918_CR262","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106\u20132112","journal-title":"Lancet"},{"key":"8918_CR263","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"8918_CR264","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J et al (2019) Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder. N Engl J Med 381:614\u2013625","journal-title":"N Engl J Med"},{"key":"8918_CR265","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","volume":"30","author":"M Reindl","year":"2017","unstructured":"Reindl M, Jarius S, Rostasy K, Berger T (2017) Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they? Curr Opin Neurol 30:295\u2013301","journal-title":"Curr Opin Neurol"},{"key":"8918_CR266","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1007\/s00115-018-0607-0","volume":"89","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J et al (2018) MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. Nervenarzt 89:1388\u20131399","journal-title":"Nervenarzt"},{"key":"8918_CR267","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2018.00217","volume":"9","author":"GR dos Passos","year":"2018","unstructured":"dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K et al (2018) MOG-IgG-associated optic neuritis, encephalitis, and myelitis: Lessons learned from neuromyelitis optica spectrum disorder. Front Neurol 9:1\u201310","journal-title":"Front Neurol"},{"key":"8918_CR268","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, De Haidar Jorge FM, Takahashi T et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474\u2013481","journal-title":"Neurology"},{"key":"8918_CR269","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","volume":"89","author":"EM Hennes","year":"2017","unstructured":"Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A et al (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89:900\u2013908","journal-title":"Neurology"},{"key":"8918_CR270","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","volume":"75","author":"AS L\u00f3pez-Chiriboga","year":"2018","unstructured":"L\u00f3pez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP et al (2018) Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG\u2013associated disorders. JAMA Neurol 75:1355\u20131363","journal-title":"JAMA Neurol"},{"key":"8918_CR271","doi-asserted-by":"crossref","unstructured":"Graus F, Saiz A, Dalmau J (2020) GAD antibodies in neurological disorders \u2014 insights and challenges. Nat Rev Neurol 16:353\u2013365","DOI":"10.1038\/s41582-020-0359-x"},{"key":"8918_CR272","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2015.0749","volume":"72","author":"H Ari\u00f1o","year":"2015","unstructured":"Ari\u00f1o H, H\u00f6ftberger R, Gresa-Arribas N, Mart\u00ednez-Hern\u00e1ndez E, Armangue T, Kruer MC et al (2015) Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol 72:1\u20138","journal-title":"JAMA Neurol"},{"key":"8918_CR273","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, Bastiaansen AEM, Nagtzaam MMP, Hulsenboom ESP et al (2020) Neurologic syndromes related to anti-GAD65. Neurol Neuroimmunol Neuroinflammation 7:e696","DOI":"10.1212\/NXI.0000000000000696"},{"key":"8918_CR274","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1708712","volume":"378","author":"J Dalmau","year":"2018","unstructured":"Dalmau J, Graus F (2018) Antibody-mediated encephalitis. N Engl J Med 378:840\u2013851","journal-title":"N Engl J Med"},{"key":"8918_CR275","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391\u2013404","journal-title":"Lancet Neurol"},{"key":"8918_CR276","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.autrev.2013.10.016","volume":"13","author":"MH Van Coevorden-Hameete","year":"2014","unstructured":"Van Coevorden-Hameete MH, de Graaff E, Titulaer MJ, Hoogenraad CC, Sillevis Smitt PAE (2014) Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system. Autoimmun Rev 13:299\u2013312","journal-title":"Autoimmun Rev"},{"key":"8918_CR277","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000245","volume":"3","author":"JJ Linnoila","year":"2016","unstructured":"Linnoila JJ, Binnicker MJ, Majed M, Klein CJ, McKeon A (2016) CSF herpes virus and autoantibody profiles in the evaluation of encephalitis. Neurol Neuroimmunol NeuroInflammation 3:1\u201310","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"8918_CR278","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1111\/ene.13332","volume":"24","author":"D Danieli","year":"2017","unstructured":"Danieli D, Moraes ACM, Alves MP, Dutra LA, H\u00f6ftberger R, Barsottini OGP et al (2017) Anti-N-methyl-D-aspartate receptor encephalitis and Epstein-Barr virus: Another tale on autoimmunity? Eur J Neurol 24:e46\u2013e47","journal-title":"Eur J Neurol"},{"key":"8918_CR279","doi-asserted-by":"crossref","unstructured":"Dutra LA, Abrantes F, Toso FF, Pedroso JL, Barsottini OGP, Hoftberger R (2018) Autoimmune encephalitis: a review of diagnosis and treatment. Arq Neuropsiquiatr 76:41\u201349","DOI":"10.1590\/0004-282x20170176"},{"key":"8918_CR280","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S1473-3099(10)70222-X","volume":"10","author":"J Granerod","year":"2010","unstructured":"Granerod J, Ambrose HE, Davies NWS, Clewley JP, Walsh AL, Morgan D et al (2010) Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 10:835\u2013844","journal-title":"Lancet Infect Dis"},{"key":"8918_CR281","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/cid\/cir1038","volume":"54","author":"MS Gable","year":"2012","unstructured":"Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA (2012) The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California encephalitis project. Clin Infect Dis 54:899\u2013904","journal-title":"Clin Infect Dis"},{"key":"8918_CR282","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Armangu\u00e9 T, Glaser C, Iizuka T et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157\u2013165","journal-title":"Lancet Neurol"},{"key":"8918_CR283","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ana.25131","volume":"83","author":"D Dubey","year":"2018","unstructured":"Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA et al (2018) Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 83:166\u2013177","journal-title":"Ann Neurol"},{"key":"8918_CR284","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1212\/WNL.0b013e3182698cd8","volume":"79","author":"SE Schmitt","year":"2012","unstructured":"Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D (2012) Extreme delta brush; a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 79:1094\u20131100","journal-title":"Neurology"},{"key":"8918_CR285","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1212\/WNL.0000000000006783","volume":"92","author":"R Balu","year":"2019","unstructured":"Balu R, Mccracken L, Lancaster E, Graus F, Dalmau J, Titulaer MJ (2019) A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology 92:e244\u2013e252","journal-title":"Neurology"},{"key":"8918_CR286","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","volume":"87","author":"A Van Sonderen","year":"2016","unstructured":"Van Sonderen A, Ari\u00f1o H, Petit-Pedrol M, Leypoldt F, K\u00f6rtv\u00e9lyessy P, Wandinger KP et al (2016) The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87:521\u2013528","journal-title":"Neurology"},{"key":"8918_CR287","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(16)31459-3","volume":"389","author":"TC Vale","year":"2017","unstructured":"Vale TC, Pedroso JL, Dutra LA, Azevedo L, Filho LHP, Prado LBF et al (2017) Morvan syndrome as a paraneoplastic disorder of thymoma with anti-CASPR2 antibodies. Lancet 389:1367\u20131368","journal-title":"Lancet"},{"key":"8918_CR288","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1212\/WNL.0000000000002476","volume":"86","author":"AS Lopez-Chiriboga","year":"2016","unstructured":"Lopez-Chiriboga AS, Komorowski L, K\u00fcmpfel T, Probst C, Hinson SR, Pittock SJ et al (2016) Metabotropic glutamate receptor type 1 autoimmunity. Neurology 86:1009\u20131013","journal-title":"Neurology"},{"key":"8918_CR289","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1212\/WNL.0000000000001682","volume":"84","author":"R H\u00f6ftberger","year":"2015","unstructured":"H\u00f6ftberger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind MD, Gelfand J et al (2015) Encephalitis and AMPA receptor antibodies. Neurology 84:2403\u20132412","journal-title":"Neurology"},{"key":"8918_CR290","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","volume":"13","author":"L Sabater","year":"2014","unstructured":"Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E et al (2014) A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 13:575\u2013586","journal-title":"Lancet Neurol"},{"key":"8918_CR291","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1212\/WNL.0000000000002775","volume":"86","author":"N Gresa-Arribas","year":"2016","unstructured":"Gresa-Arribas N, Planagum\u00e0 J, Petit-Pedrol M, Kawachi I, Katada S, Glaser CA et al (2016) Human neurexin-3\u03b1 antibodies associate with encephalitis and alter synapse development. Neurology 86:2235\u20132242","journal-title":"Neurology"},{"key":"8918_CR292","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1212\/WNL.0000000000003713","volume":"88","author":"M Spatola","year":"2017","unstructured":"Spatola M, Petit-Pedrol M, Simabukuro MM, Armangue T, Castro FJ, Artigues MIB et al (2017) Investigations in GABAA receptor antibody-associated encephalitis. Neurology 88:1012\u20131020","journal-title":"Neurology"},{"key":"8918_CR293","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1212\/WNL.0000000000003796","volume":"88","author":"M Hara","year":"2017","unstructured":"Hara M, Ari\u00f1o H, Petit-Pedrol M, Sabater L, Titulaer MJ, Hernandez EM et al (2017) DPPX antibody-associated encephalitis main syndrome and antibody effects. Neurology 88:1340\u20131348","journal-title":"Neurology"},{"key":"8918_CR294","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1212\/WNL.0b013e3182a9585f","volume":"81","author":"R H\u00f6ftberger","year":"2013","unstructured":"H\u00f6ftberger R, Titulaer MJ, Sabater L, Dome B, R\u00f3zs\u00e1s A, Hegedus B et al (2013) Encephalitis and GABAB receptor antibodies: Novel findings in a new case series of 20 patients. Neurology 81:1500\u20131506","journal-title":"Neurology"},{"key":"8918_CR295","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","volume":"87","author":"A Van Sonderen","year":"2016","unstructured":"Van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, De Bruijn MAAM et al (2016) Anti-LGI1 encephalitis. Neurology 87:1449\u20131456","journal-title":"Neurology"},{"key":"8918_CR296","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaneurol.2013.3216","volume":"70","author":"MS Kayser","year":"2013","unstructured":"Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J (2013) Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 70:1133\u20131139","journal-title":"JAMA Neurol"},{"key":"8918_CR297","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0022-1759(98)00140-9","volume":"219","author":"N Bizzaro","year":"1998","unstructured":"Bizzaro N, Tozzoli R, Tonutti E, Piazza A, Manoni F, Ghirardello A et al (1998) Variability between methods to determine ANA, anti-dsDNA and anti-ENA auto antibodies: a collaborative study with the biomedical industry. J Immunol Methods 219:99\u2013107","journal-title":"J Immunol Methods"},{"key":"8918_CR298","first-page":"203","volume":"437","author":"KM Pereira","year":"2014","unstructured":"Pereira KM, Dellavance A, Andrade LE (2014) The challenge of identification of autoantibodies specific to systemic autoimmune rheumatic diseases in high throughput operation: Proposal of reliable and feasible strategies. J Immunol Methods 437:203\u2013210","journal-title":"J Immunol Methods"},{"key":"8918_CR299","doi-asserted-by":"crossref","unstructured":"Mummert E, Fritzler MJ, Sjowall C, Bentow C, Mahler M (2018) The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. J Immunol Methods 459:11\u201319","DOI":"10.1016\/j.jim.2018.05.014"},{"key":"8918_CR300","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/sji.12414","volume":"83","author":"S Avrameas","year":"2016","unstructured":"Avrameas S (2016) Autopolyreactivity confers a holistic role in the immune system. Scand J Immunol 83:227\u2013234","journal-title":"Scand J Immunol"},{"key":"8918_CR301","doi-asserted-by":"crossref","unstructured":"Nagele EP, Han M, Acharya NK, DeMarshall C, Kosciuk MC, Nagele RG (2013) Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One 8:e60726","DOI":"10.1371\/journal.pone.0060726"},{"key":"8918_CR302","volume-title":"A practical guide to ELISA","author":"DM Kemeny","year":"1991","unstructured":"Kemeny DM (1991) A practical guide to ELISA. Pergamon Press, Oxford, England"},{"key":"8918_CR303","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1177\/0961203316640367","volume":"25","author":"MY Choi","year":"2016","unstructured":"Choi MY, Barber MR, Barber CE, Clarke AE, Fritzler MJ (2016) Preventing the development of SLE: Identifying risk factors and proposing pathways for clinical care. Lupus 25:838\u2013849","journal-title":"Lupus"},{"key":"8918_CR304","doi-asserted-by":"crossref","unstructured":"Bossuyt X, Claessens J, Belmondo T, De Langhe E, Westhovens R, Poesen K et al (2019) Harmonization of clinical interpretation of antinuclear antibody test results by solid phase assay and by indirect immunofluorescence through likelihood ratios. Autoimmun Rev 18:102386","DOI":"10.1016\/j.autrev.2019.102386"},{"key":"8918_CR305","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/0090-1229(85)90045-5","volume":"36","author":"MJ Fritzler","year":"1985","unstructured":"Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ (1985) Antinuclear, anticytoplasmic, and anti-Sj\u00f6gren\u2019s syndrome antigen A (SS-A\/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 36:120\u2013128","journal-title":"Clin Immunol Immunopathol"},{"key":"8918_CR306","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/art.20096","volume":"50","author":"A Watanabe","year":"2004","unstructured":"Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y et al (2004) Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 50:892\u2013900","journal-title":"Arthritis Rheum"},{"key":"8918_CR307","first-page":"2144","volume":"32","author":"A Dellavance","year":"2005","unstructured":"Dellavance A, Viana VS, Leon EP, Bonfa ES, Andrade LE, Leser PG (2005) The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol 32:2144\u20132149","journal-title":"J Rheumatol"},{"key":"8918_CR308","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0022-5347(17)35023-1","volume":"151","author":"RL Ochs","year":"1994","unstructured":"Ochs RL, Stein TW Jr, Peebles CL, Gittes RF, Tan EM (1994) Autoantibodies in interstitial cystitis. J Urol 151:587\u2013592","journal-title":"J Urol"},{"key":"8918_CR309","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/0891693021000003198","volume":"35","author":"M Ayaki","year":"2002","unstructured":"Ayaki M, Ohoguro N, Azuma N, Majima Y, Yata K, Ibaraki N et al (2002) Detection of cytotoxic anti-LEDGF autoantibodies in atopic dermatitis. Autoimmunity 35:319\u2013327","journal-title":"Autoimmunity"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08918-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-021-08918-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08918-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T13:25:44Z","timestamp":1673529944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-021-08918-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":309,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["8918"],"URL":"https:\/\/doi.org\/10.1007\/s12016-021-08918-6","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"22 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}